Orexin A and the wakefulness system — narcolepsy and the inverse story

In 1998, two research groups published papers that together produced one of the more remarkable coincidences in modern neuroscience. Masashi Yanagisawa at the University of Texas Southwestern and Luis de Lecea at the Salk Institute each identified a hypothalamic neuropeptide system they had discovered independently. Yanagisawa's group named it orexin, for its apparent role in appetite regulation — the Greek root for appetite. De Lecea's group named it hypocretin, noting its location in the hypothalamus and structural similarity to secretin. The two names persist in the literature today, used interchangeably and occasionally confusingly. Orexin A and orexin B are the two peptides produced; hypocretin-1 and hypocretin-2 are the same molecules. The neurons producing them — roughly 50,000 to 80,000 in the human hypothalamus, an almost impossibly small population for a system with such broad effects — project throughout the brain.

Mignot's genetic work on the narcoleptic Dobermans converged with this discovery almost immediately. The mutation causing narcolepsy in the Stanford colony was in the hypocretin receptor gene. Shortly after, he and Seiji Nishino demonstrated that humans with narcolepsy had dramatically reduced levels of orexin in their cerebrospinal fluid. The mechanism of narcolepsy, long mysterious, suddenly had an answer: autoimmune destruction of the hypothalamic neurons that produce orexin A and orexin B. The immune system had attacked and eliminated the cells responsible for maintaining wakefulness signaling, and the result was exactly what you'd predict if you suddenly lost wakefulness regulation: intrusions of REM sleep into waking states, sudden muscle paralysis triggered by emotion (cataplexy, a defining feature of narcolepsy type 1), disrupted nighttime sleep, and the profound daytime sleepiness that defines the condition.

The elegance of this finding was that it gave a mechanistic account of wakefulness itself — not just of narcolepsy. If loss of orexin causes narcolepsy, then orexin, while it's present and functioning, is doing something essential to maintaining the awake state. The orexin system turned out to be not a simple on-off switch for wakefulness but a stabilizer — a signal that holds the brain in a waking state and prevents unwanted transitions into sleep. Think of wakefulness and sleep as two stable states between which the brain must choose, and orexin as the mechanism that makes the waking state stable, that prevents it from collapsing unexpectedly into sleep in response to emotional activation or low arousal.

The orexin system projects to nearly every major arousal-related region in the brainstem and forebrain. It activates noradrenergic neurons in the locus coeruleus, serotonergic neurons in the raphe nuclei, histaminergic neurons in the tuberomammillary nucleus, and dopaminergic neurons in the ventral tegmental area. It integrates signals from these classical arousal systems into a coordinated wakefulness state. It also connects to reward circuitry, to appetite regulation, and to stress-response systems — which explains why the consequences of orexin loss aren't limited to sleepiness but extend to metabolic disruption and altered reward processing. Many people with narcolepsy have higher rates of obesity; the orexin system's role in energy balance and appetite turns out to be significant.

The therapeutic implications ran immediately in two directions, and this is the unusual feature of the orexin story: the same system is relevant to treating both insomnia and narcolepsy, but from opposite sides. If orexin promotes wakefulness, then orexin antagonists — drugs that block orexin receptors — should promote sleep. This logic led directly to the development of suvorexant (Belsomra), which the FDA approved in 2014 for insomnia, making it the first approved orexin receptor antagonist. Lemborexant followed in 2019. These are sleep drugs that work not by sedating the brain globally but by specifically turning off the wakefulness-stabilizing signal. The sleep they produce is structurally different from benzodiazepine or Z-drug sleep: rather than global neural suppression, they allow the brain's natural sleep machinery to take over once the orexin-driven wakefulness signal is removed.

The other direction — orexin agonists for narcolepsy — proved more pharmacologically difficult. Replacing orexin signaling when the neurons that produce it have been destroyed is a harder problem than blocking a receptor. Small molecules that activate orexin receptors had to be developed; they couldn't simply be orexin A itself, because peptides don't readily cross the blood-brain barrier following peripheral administration. Takeda's TAK-994, an orexin receptor 2 agonist taken orally, showed striking efficacy in phase 2 narcolepsy trials — essentially reversing cataplexy and improving wakefulness significantly — before development was paused due to liver toxicity findings in preclinical studies. The program resumed with structural modifications. Multiple companies are pursuing orexin agonists or selective orexin receptor 2 agonists for narcolepsy type 1, and the therapeutic case is strong: replacing the lost signal with a drug that mimics it would, in principle, address the root mechanism of the disease rather than just managing symptoms with stimulants.

Narcolepsy treatment today primarily involves modafinil or armodafinil for wakefulness, sodium oxybate (GHB) for nighttime sleep consolidation and cataplexy, and sometimes amphetamine-class stimulants — all of which work around the absent orexin signal rather than through it. Orexin agonists, if they can be developed safely, represent a more targeted solution to a problem that is now mechanistically understood in a way it wasn't before 1998.

The intranasal orexin story occupies a different space — not therapeutic replacement in clinical narcolepsy, but the question of whether delivering orexin A directly via nasal route can enhance wakefulness and cognitive performance in people whose orexin system is intact but under strain. Sleep deprivation reduces effective orexin signaling; the fatigue and cognitive impairment of sleep loss overlap with the profile of reduced orexin tone. Intranasal delivery was proposed because it might allow orexin A to reach hypothalamic and brainstem targets via olfactory and trigeminal pathways, partially bypassing the blood-brain barrier problem that limits peripheral peptide delivery. The research on this application is preliminary — preclinical work and a small number of human studies — and will be addressed specifically in the context of fatigue and cognitive performance.

The broader lesson of the orexin discovery is about what happens when a key biological regulator is identified not through normal discovery but through its absence. Narcolepsy was the pathology that revealed the system. The narcoleptic dogs at Stanford, the genetic work that identified the hypocretin receptor mutation, Mignot's CSF findings in human narcolepsy — these were the clues that exposed orexin as the architecture of wakefulness itself. This is a recurring pattern in neuroscience: we learn what a system does by seeing what fails when it's gone. The cost of that lesson, in narcolepsy, is paid by people whose immune systems silently eliminated tens of thousands of neurons that can't be replaced — neurons that spent years being described as responsible for excessive daytime sleepiness, without anyone understanding why the sleepiness existed until the discovery that orexin was missing.

What is now known about orexin's scope — its integration of wakefulness with appetite, reward, stress response, and emotional processing — suggests a system that is doing considerably more than stabilizing the awake state. It may be the mechanism by which arousal, motivation, and metabolic state are coordinated. Lose it, and the consequences are not simply excessive sleepiness: they're a fundamental disruption of the relationship between internal state and behavior. The orexin story isn't finished. The agonist development programs are ongoing; the intranasal research is exploratory; the full map of what orexin coordinates across the brain hasn't been drawn. But the shape of the question is now clear in a way it wasn't when a dog named Monty was collapsing in a Stanford laboratory.